Heart & Lung: The Journal of Acute and Critical Care
Volume 37, Issue 1 , Pages 67-71 , January 2008

The impact of carvedilol on the defibrillation threshold

  • Brian F. McBride, PharmD

      Affiliations

    • Division of Clinical Pharmacology and John A. Oates Institute for Experimental Therapeutics, Vanderbilt University School of Medicine, Nashville, Tennessee
    • ,
  • C. Michael White, PharmD, FCCP, FCP

      Affiliations

    • University of Connecticut School of Pharmacy, Storrs, Connecticut
    • Hartford Hospital Division of Cardiology and Drug Information, Hartford, Connecticut
    • ,
  • James S. Kalus, PharmD, BCPS

      Affiliations

    • University of Connecticut School of Pharmacy, Storrs, Connecticut
    • Hartford Hospital Division of Cardiology and Drug Information, Hartford, Connecticut
    • ,
  • Danette C. Guertin, MSN, APRN

      Affiliations

    • Hartford Hospital Division of Cardiology, Hartford, Connecticut
    • ,
  • Christopher A. Clyne, MD

      Affiliations

    • Hartford Hospital Division of Cardiology, Hartford, Connecticut
    • ,
  • William L. Baker, PharmD, BCPS

      Affiliations

    • Hartford Hospital/University of Connecticut, Hartford, Connecticut
    • ,
  • Jeffery Kluger, MD, FACC

      Affiliations

    • Hartford Hospital Division of Cardiology, Hartford, Connecticut
    • University of Connecticut School of Medicine; Farmington, Connecticut.
    • Corresponding Author InformationReprint requests: Jeffrey Kluger, MD, FACC, Hartford Hospital, 80 Seymour Street Suite 1001 Hartford, CT 06102-5037.

References 

  1. Greenberg H, Case RB, Moss AJ, Brown MW, Carroll ER, Andrews ML, et al. Analysis of mortality events in the Multicenter Automatic Defibrillator Implantation Trial (MADIT II). J Am Coll Cardiol. 2004;43:1459–1465
  2. Ideker RE, Wolf PD, Tang AS. Mechanisms of defibrillation. In:  Tacker WA editors. Defibrillation of the Heart. St. Louis, MO: Mosby-Year Book, Inc; 1994;p. 15–45
  3. Guarnieri T, Levine JH, Veltri EP, Griffith LS, Watkins LJR, Juanteguy J, et al. Success of chronic defibrillation and the role of antiarrhythmic drugs with the automatic implantable cardioverter/defibrillator. Am J Cardiol. 1987;60:1061–1064
  4. Babbs CF. Effects of drugs on defibrillation threshold. In:  Tacker WA editors. Defibrillation of the Heart. St. Louis, MO: Mosby-Year Book, Inc; 1994;p. 223–258
  5. Morady F, Nelson SD, Kou WH, Pratley R, Schmaltz S, De Buitleir M, et al. Electrophysioligc effects of epinephrine in humans. J Am Coll Cardiol. 1988;11:1235–1244
  6. Sousa J, Kou W, Calkins H, Rosenheck S, Kadish A, Morady F. Effect of epinephrine on the efficacy of the internal cardioverter-defibrillator. Am J Cardiol. 1992;69:509–512
  7. Kalus JS, White CM, Caron MF, Guertin DC, McBride BF, Kluger J. The impact of elevations in catecholamine concentrations on defibrillation threshold in patients with implanted cardioverter-defibrillators. PACE. 2005;28:1147–1156
  8. Albert C, Mittleman MA, Chae CU, Lee IM, Hennekens CH, Manson JE. Triggering of sudden death from cardiac causes by vigorous exertion. N Engl J Med. 2000;343:1355–1361
  9. Frishman WH. Alpha- and beta-blocking drugs. In:  Frishman WH,  Sonneblick EH,  Sica DA editor. Cardiovascular Pharmacotherapeutics Manual. Second Edition. New York, NY: McGraw-Hill; 2004;p. 19–57
  10. Pharand C, Goldman R, Fan C, Chow M, Kluger J. Effect of chronic oral moricizine and intravenous epinephrine on ventricular fibrillation and defibrillation thresholds. PACE. 1996;19:82–89
  11. Morillo CA, Jones DL, Klein GJ. Effects of autonomic manipulation on ventricular fibrillation and internal cardiac defibrillation threshold in pigs. PACE. 1996;19:1355–1362

 This study was funded by a Hartford Hospital Research Grant.

PII: S0147-9563(07)00090-8

doi: 10.1016/j.hrtlng.2007.04.005

Heart & Lung: The Journal of Acute and Critical Care
Volume 37, Issue 1 , Pages 67-71 , January 2008

Article Tools